Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives $43.33 Consensus Target Price from Analysts

Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) has been assigned a consensus recommendation of "Buy" from the six ratings firms that are covering the company, MarketBeat reports. Five equities research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $43.33.

Several equities research analysts have recently weighed in on the stock. Rodman & Renshaw assumed coverage on shares of Bicara Therapeutics in a report on Tuesday. They issued a "buy" rating and a $48.00 target price on the stock. Morgan Stanley assumed coverage on shares of Bicara Therapeutics in a report on Tuesday, October 8th. They issued an "overweight" rating and a $35.00 target price on the stock. Cantor Fitzgerald assumed coverage on shares of Bicara Therapeutics in a report on Tuesday, October 8th. They issued an "overweight" rating on the stock. Stifel Nicolaus assumed coverage on shares of Bicara Therapeutics in a report on Tuesday, October 8th. They set a "buy" rating and a $47.00 price objective on the stock. Finally, RODMAN&RENSHAW raised shares of Bicara Therapeutics to a "strong-buy" rating in a report on Tuesday.

Bicara Therapeutics Stock Down 5.6 %

Shares of BCAX traded down $1.42 during trading hours on Wednesday, hitting $23.77. The stock had a trading volume of 371,254 shares, compared to its average volume of 379,802. Bicara Therapeutics has a 52 week low of $18.33 and a 52 week high of $28.09.

Insiders Place Their Bets

In other Bicara Therapeutics news, major shareholder James E. Flynn bought 70,000 shares of Bicara Therapeutics stock in a transaction dated Tuesday, September 17th. The shares were bought at an average price of $18.00 per share, with a total value of $1,260,000.00. Following the purchase, the insider now owns 897,587 shares of the company's stock, valued at $16,156,566. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. In other Bicara Therapeutics news, major shareholder James E. Flynn bought 70,000 shares of Bicara Therapeutics stock in a transaction dated Tuesday, September 17th. The shares were bought at an average price of $18.00 per share, with a total value of $1,260,000.00. Following the purchase, the insider now owns 897,587 shares of the company's stock, valued at $16,156,566. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Ra Capital Management, L.P. bought 1,833,000 shares of Bicara Therapeutics stock in a transaction dated Monday, September 16th. The stock was acquired at an average cost of $18.00 per share, for a total transaction of $32,994,000.00. Following the purchase, the director now directly owns 4,303,418 shares in the company, valued at approximately $77,461,524. The trade was a 0.00 % increase in their position. The disclosure for this purchase can be found here.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.